Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiologyheart failure, electrophysiologyhypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

Thumbnail

MRI and mass spectrometry imaging to play key role in Alzheimer's research

By combining MSI results with whole-brain MRI exams, researchers are hoping to gain insight into the development of Alzheimer’s disease on a molecular level. 

covid-19 coronavirus

PCSK9 inhibition may reduce risk of death for patients with severe COVID-19

JACC pilot study suggests possible benefits for patients with severe cases of COVID-19 infection. 

Thumbnail

Healthcare bankruptcies jumped 84% in 2022

Large bankruptcies in the healthcare industry rose sharply from 2021 to 2022, according to a new report from healthcare restructuring firm Gibbons Advisors.

Cleveland Clinic CEO warns of $200M loss in 2022

Cleveland Clinic CEO and President Tom Mihaljevic, MD, gave the healthcare organization’s State of the Clinic speech on Jan. 18, sharing optimism for the company’s future despite a $200 million loss in 2022.

Thumbnail

Intermittent fasting not associated with long-term weight loss, according to new 6-year analysis

Reducing total calorie intake and minimizing large meals, on the other hand, were both linked to improved weight loss. The study followed participants for an average of 6.3 years. 

Thumbnail

EHR intervention targets acute kidney injuries after PCI

Contrast-associated acute kidney injury is a significant problem in cardiology, especially among patients undergoing percutaneous coronary intervention. Can EHR-generated alerts make an impact?

Deep learning slashes real-world MRI scan times

Accelerated MRI with AI image reconstruction nearly halved orthopedic scan times while maintaining or even improving image quality in a newly published prospective study. 

Peter Libby, MD, a cardiovascular medicine specialist, Brigham and Women’s Hospital, and Mallinckrodt Professor of Medicine, Harvard Medical School, explains the take aways from the PROMINENT trial using pemafibrate to lower cardiovascular risks. The trial, presented at the American Heart Association (AHA) 2022 meeting, did not show reduction in the incidence of cardiovascular events among those who received pemafibrate than among those who received placebo. #AHA #AHA22

VIDEO: Pemafibrate does not lower cardiovascular risks in the PROMINENT trial

Peter Libby, MD, a cardiovascular medicine specialist with Brigham and Women’s Hospital and Harvard Medical School, explained some key takeaways from the PROMINENT trial.